###### Strengths and limitations of this study

-   The YOu and Ulcerative colitis: Registry and Social network (YOURS) study is a large-scale, long-term, prospective observational study to explore optimal ulcerative colitis management for improving relevant outcomes.

-   The YOURS study reflects the real clinical setting because any concomitant drugs and therapies are allowed.

-   The YOURS study can be expanded for subsequent surveys because patients and healthcare professionals can ask research questions not otherwise included in the survey.

-   Patients will be able to access their own data and compare them with summarised data from all patients on the website beyond the YOURS study.

-   All investigational sites are located within one region of Japan, which may affect the study results, especially because of lifestyle and psychosocial factors.

Introduction {#s1}
============

Ulcerative colitis (UC) is a chronic inflammatory disease with no curative treatment. It mainly affects the colon and is associated with bloody diarrhoea and faecal urgency as typical symptoms.[@R1] Aberrant immunity in the gut is considered to be involved in the pathogenesis of UC;[@R2] however, the aetiology of UC is not fully understood. UC is increasing around the world, especially in Asia, including Japan.[@R3] The prevalence of UC has been reported to range from 5.3 to 63.6 per 100 000 people in Asia and from 37.5 to 238 per 100 000 people in North America,[@R1] and differs between regions, with the prevalence in Japan reported as approximately 100 per 100 000 people in 2013.[@R5]

The onset of UC often has a major influence on patients' quality of life (QOL), and intractable UC can lead to hospitalisation and colectomy. Patients need to manage UC throughout their lives with both self-management and support from healthcare professionals (HCPs) to avoid unwanted clinical outcomes, including relapse/exacerbation, hospitalisation, and colectomy, as well as to improve patient-reported outcomes such as QOL.

In this YOURS (YOu and Ulcerative colitis: Registry and Social network) study, we identified four main factors/challenges to the improvement of patient outcomes: (1) lifestyle, (2) psychosocial factors, (3) practice patterns and (4) gaps between patients' needs and HCPs' practice ([figure 1](#F1){ref-type="fig"}).

![Factors and outcomes assessed in the YOURS study. All four factors can contribute to all four outcomes. HCP, healthcare professional; YOURS, YOu and Ulcerative colitis: Registry and Social network.](bmjopen-2019-030134f01){#F1}

First, there has been much discussion and debate about the optimal lifestyle (diet, exercise, sleep and work) for UC management. In particular, diet is a critical issue for both patients and their HCPs. Although a large-scale study has reported that the relationship between diet and relapse is of major interest to patients with inflammatory bowel disease (IBD) and their HCPs,[@R6] only two exploratory studies have examined the relationship.[@R7] However, the results from these studies were not consistent.

Second, psychosocial factors including stress, depression and social support may affect clinical outcomes in UC. Approximately half of patients with IBD have low QOL and depression,[@R9] and one-third of patients are reported to feel stigmatised.[@R10] It remains unknown how these psychosocial factors affect disease course.

The third challenge is practice patterns. The Selecting Therapeutic Targets in Inflammatory Bowel Disease programme, published in 2015 by IBD specialists, recommends setting concrete treatment goals as part of a 'Treat to Target' strategy.[@R11] The agreed treatment goals for UC were clinical remission (defined as resolution of rectal bleeding and diarrhoea/altered bowel habit) and endoscopic remission (based on endoscopic findings). However, achievement of these treatment goals may be accompanied by decreased QOL due to frequent colonoscopies or side effects caused by immune suppression. Optimal disease monitoring and treatment need to be clarified.

The last challenge is gaps between patients' needs and HCPs' practice. A previous survey has identified important differences between patients and HCPs in their perception of the impact of UC symptoms on patients' lives, suggesting that HCPs may underestimate the effect of UC symptoms on patients.[@R12] However, the effect of perception gaps on patient outcomes is unknown.

The YOURS study is an observational prospective cohort study in patients with UC in Japan that aims to clarify how these four challenges affect relapse/exacerbation, hospitalisation, colectomy and patient-reported outcomes such as QOL.

Methods and analysis {#s2}
====================

Study design {#s2-1}
------------

The YOURS study is an observational prospective cohort study with a 3-year follow-up being conducted at five investigational sites in Japan. Patient registration started in May 2018 and ended in January 2019. As of 11 January 2019, 2006 patients have been enrolled.

The study is being conducted in compliance with the Declaration of Helsinki, Ethical Guidelines for Medical Research on Humans, Ministry of Education, Culture, Sports, Science and Technology of Japan and Ministry of Health, Labour and Welfare of Japan and all applicable laws and guidelines. Written informed consent will be obtained from all patients. The study is registered at the University hospital Medical Information Network (UMIN) Center.

Study population and sample size {#s2-2}
--------------------------------

Patients diagnosed with UC, as defined by the 'Evidence-based Clinical Practice Guidelines for Inflammatory Bowel Disease',[@R5] who are ≥16 years of age at informed consent and are attending the investigational sites are eligible for enrolment.

The sample size was determined by considering the feasibility of enrolling patients.

Outcome measures and survey items {#s2-3}
---------------------------------

Relapse/exacerbation, hospitalisation, colectomy and patient-reported outcomes such as QOL will be assessed as main outcomes. Lifestyle, psychosocial factors, practice patterns and gaps between patients' needs and HCPs' practice will be evaluated as exposures. All surveys will be conducted in Japanese and will include standard, validated questionnaires for most measures of lifestyle, psychosocial factors and symptoms.

At the initial survey, patients will complete written questionnaires with demographic, lifestyle, psychosocial and symptom questions ([table 1](#T1){ref-type="table"}, [figure 2](#F2){ref-type="fig"}). Following the initial survey, patients will complete a three-item brief symptom survey including psychosocial and symptom questions by smartphone application, email, phone or written questionnaire every 3 months, and a follow-up survey including lifestyle, psychosocial and symptom questions by written questionnaire every year for 3 years ([table 1](#T1){ref-type="table"}, [figure 2](#F2){ref-type="fig"}). Patients who maintain remission for at least 90 days will complete a special survey by written questionnaire at 3 months from the time of the initial survey, which includes lifestyle questions focusing on diet, exercise and stress management as strategies to prevent relapse ([table 1](#T1){ref-type="table"}, [figure 2](#F2){ref-type="fig"}). Remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0 (two-item patient-reported outcome; [table 2](#T2){ref-type="table"}).[@R13] Patients will have the opportunity to provide their own research questions at the initial survey and all follow-up surveys. We plan to categorise and create a ranking of the research questions. The members of the steering committee will review the ranking of these research questions. If the research questions are feasible for this study, they will be included in the subsequent surveys within the YOURS study. The three-item brief symptom survey will provide the most important information for this study because the survey evaluates relapse or exacerbation of UC. In cases where patients are reluctant to complete the follow-up survey, for reasons such as changing hospitals, we will offer to continue with only the brief symptom survey every 3 months to reduce the number of dropouts.

###### 

Survey items/questionnaires

                                                                                                                 Category                                                                                                                                                                Item (questionnaire)
  -------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *By patients*                                                                                                                                                                                                                                                                          
   Initial survey                                                                                                Patient information                                                                                                                                                     Body height, weight, UC history, appendectomy, medical history including malignant tumour, anal fistula and perianal abscess, family history of inflammatory bowel disease, vaccination history, smoking history, education level, economic status and pregnancy history
  Lifestyle                                                                                                      Exercise (IPAQ), sleep (PSQI) and labour productivity (WPAI)                                                                                                            
  Psychosocial factors                                                                                           Social support (mMOS-SS), medication adherence (ASK-12), comprehensive QOL (QGEN10 survey), disease-specific QOL (SIBDQ), depression/anxiety (HADS) and stress (JPSS)   
  Symptoms                                                                                                       Stool frequency and rectal bleeding (PRO-2), pain (NRS) and fatigue (FACIT-F)                                                                                           
  Others                                                                                                         Research questions not included in this survey                                                                                                                          
   Special survey (in patients in remission for at least 90 days, at 3 months from the time of initial survey)   Lifestyle                                                                                                                                                               Diet (BDHQ)
  Others                                                                                                         Diet, exercise and stress management strategies to prevent relapse                                                                                                      
   Symptom survey (every 3 months)                                                                               Psychosocial factors                                                                                                                                                    Disease-specific QOL (QDIS−1)
  Symptoms                                                                                                       Stool frequency and rectal bleeding (PRO-2)                                                                                                                             
   Follow-up survey (every year)                                                                                 Lifestyle                                                                                                                                                               Sleep (PSQI) and labour productivity (WPAI)
  Psychosocial factors                                                                                           Medication adherence (ASK-12), comprehensive QOL (QGEN10 survey), disease-specific QOL (SIBDQ), depression/anxiety (HADS) and stress (JPSS)                             
  Symptoms                                                                                                       Stool frequency and rectal bleeding (PRO-2), pain (NRS) and fatigue (FACIT-F)                                                                                           
  Others                                                                                                         Research questions not included in this survey                                                                                                                          
  *By HCP*                                                                                                                                                                                                                                                                               
   HCP survey (initial)                                                                                          --                                                                                                                                                                      Observations related to lifestyle guidance for diet, exercise and strategies to avoid stress; research questions not included in this survey
   Medical record survey (initial only)                                                                          Patient information                                                                                                                                                     Age, sex, worst disease extent (eg, pancolitis, left-sided colitis, extensive colitis), extraintestinal complications and treatment history
   Medical record survey (initial, 3 months from the initial survey, every year)                                 Medical information                                                                                                                                                     Partial Mayo score, medication, observation of endoscope and pathologic observation, *Clostridium difficile* infection, blood examination, calprotectin in stool, hospitalisation, colectomy, pregnancy, adverse events and malignancy

ASK-12,[@R15] Adherence Starts with Knowledge-12; BDHQ,[@R19] Brief-type self-administered Diet History Questionnaire; FACIT-F,[@R21] Functional Assessment of Chronic Illness Therapy-Fatigue; HADS,[@R24] Hospital Anxiety and Depression Scale; HCP, healthcare professional; IPAQ,[@R28] International Physical Activities Questionnaire; JPSS,[@R30] Japanese version of the Perceived Stress Scale; mMOS-SS,[@R32] modified Medical Outcomes Study Social Support Survey; NRS,[@R35] Numerical Rating Scale; PRO-2,[@R13] two-item patient-reported outcomes; PSQI,[@R36] Pittsburgh Sleep Quality Index; QDIS,[@R38] Quality of life Disease-specific Impact Scale; QGEN,[@R39] Quality of life GENeral; QOL, quality of life; SIBDQ,[@R40] Short version of Inflammatory Bowel Disease Questionnaire; UC, ulcerative colitis; WPAI,[@R43] Work Productivity and Activity Impairment questionnaire.

###### 

Definition of stool frequency score and rectal bleeding score in PRO-2

  Score             Definition
  ----------------- -----------------------------------------------------
  Stool frequency   
   0                Normal number of stools
   1                1--2 stools more than normal
   2                3--4 stools more than normal
   3                5 or more stools more than normal
  Rectal bleeding   
   0                None
   1                Streaks of blood with stool less than half the time
   2                Obvious blood with stool most of the time
   3                Blood alone passed

PRO-2, two-item patient-reported outcomes.

![Study design. Surveys on the left side are for patients, and surveys on the right side are for HCPs. All surveys were completed by written questionnaires, except for the symptom survey, which could be completed by smartphone application, email, phone or written questionnaire. The special survey at 3 months from the time of initial survey was only completed by patients who maintained remission for at least 90 days. HCP, healthcare professional.](bmjopen-2019-030134f02){#F2}

In the HCP survey, HCPs will complete written questionnaires about their guidance to patients with remission regarding diet, exercise and stress management in order to prevent relapse. Answers from patients and HCPs will be compared and any gaps in the perception of the ideal lifestyle to prevent relapses will be identified and explored. In addition, HCPs will collect patients' medical information such as medication use, blood examinations, stool examinations, endoscopic findings, pathologic findings, hospitalisations, colectomy status and adverse events (throughout the study) from electronic medical records at all surveys ([table 1](#T1){ref-type="table"}, [figure 2](#F2){ref-type="fig"}).

Data management {#s2-4}
---------------

The YOURS study uses an electronic data capture system to register patients, collect survey answers and create a database, which can be accessed securely by only those investigators who have received appropriate training. The principal investigators are responsible for ensuring data quality.

Feedback to patients {#s2-5}
--------------------

Patients will be provided written feedback on their data compared with the other patients participating in the YOURS study. Moreover, patients can use the website for reviewing their data over time, comparing with others and sharing their data with HCPs via the website, provided the patients have requested access and agreed to the transfer of their data from the database to the website with written informed consent ([figure 3](#F3){ref-type="fig"}).

![Feedback scheme of the YOURS study. (a) Survey answers and medical records will be collected from patients and HCPs by written questionnaire, smartphone application, email or phone, and stored in the YOURS study database. (b) Patients can use a website for reviewing their own data over time if the patients have requested access and agreed to the transfer of their data to the website. (c) Patients can also use the website for comparing their data with others, and for sharing their data with HCPs via the website. HCP, healthcare professional; YOURS, YOu and Ulcerative colitis: Registry and Social network.](bmjopen-2019-030134f03){#F3}

Statistical analysis {#s2-6}
--------------------

Analysis groups will be determined for each outcome measure and survey item. The baseline data on demographics, lifestyle, psychosocial factors, practice patterns and gaps between patients' needs and HCPs' practice will be summarised. The following statistical analyses to clarify the association of these baseline data with relapse/exacerbation, hospitalisation, colectomy and patient-reported outcomes such as QOL will be conducted.

Logistic regression analysis or Cox proportional hazard model will be used for analysis of binary variables. Linear regression analysis will be used for analysis of continuous variables. Multilevel analysis may be used for considering differences between investigational sites. Confounding factors will be adjusted appropriately for all analyses.

Interim database locks and interim analyses are planned as follows: initial survey, special survey at 3 months from the time of the initial survey, and follow-up surveys at 2 and 3 years after the initial survey.

Patient and public involvement statement {#s2-7}
----------------------------------------

We will collect research questions from both patients and HCPs from surveys in the YOURS study. If the research questions are feasible for this study, they will be included in the subsequent surveys within the YOURS study.

Ethics and dissemination {#s3}
========================

The YOURS study is sponsored by Takeda Pharmaceutical Company Limited (Tokyo, Japan) and advice on the study plan was obtained from the Japanese Society for Inflammatory Bowel Disease. The study is managed by six joint research organisations, including Takeda and five investigational sites: Tokyo Medical and Dental University, Medical Hospital (Tokyo, Japan); Kitasato University Kitasato Institute Hospital (Tokyo, Japan); Kyorin University Hospital (Tokyo, Japan); Tokyo Women\'s Medical University Hospital (Tokyo, Japan) and Toho University Sakura Medical Center (Chiba, Japan), and was approved by the ethics committees of five investigational sites before starting the study. The YOURS study has a steering committee consisting of medical experts conducting the study, representatives of the joint research organisations and clinical epidemiology experts. The roles of the steering committee are to supervise the overall study operation, provide medical expertise guidance, ensure the scientific quality of the study is at a high level and update the protocol appropriately when needed. The results will be submitted to journals for publication.

Discussion {#s4}
==========

There are four primary goals of the YOURS study: (1) develop a platform to share clinical knowledge and patient experience, (2) define optimal care for UC, (3) fill gaps between patients' needs and HCPs' practice and (4) improve relevant outcomes. To achieve these goals, the YOURS study will investigate how four main challenges (lifestyle, psychosocial factors, practice patterns and gaps between patients' needs and HCPs' practice) affect relapse/exacerbation, hospitalisation, colectomy and patient-reported outcomes such as QOL.

Using the YOURS study results, we plan to create a booklet to clarify how challenges such as lifestyle, psychosocial factors, practice patterns and gaps between patients' needs and HCPs' practice affect clinical outcomes. Although booklets are a preferred adjunct source of information for patients with IBD and it is important to distribute booklets, the same information will also be disseminated in other ways, such as websites, as needed.[@R14] The YOURS study booklet will include specific information on diet, exercise, sleep, work, stress, depression and social support. Moreover, if we identify any gaps between patients' needs and HCPs' practice regarding lifestyle guidance, we will include that information in the booklet as background information. We anticipate that the booklet will facilitate the sharing of information between patients and HCPs, thereby helping to bridge gaps between patients' needs and HCPs' practice.

The YOURS study is a large-scale, long-term, prospective observational study without any prohibited concomitant drugs and therapies, thereby reflecting real clinical settings. However, as all investigational sites are located in Tokyo or Chiba (which is near Tokyo) in Japan, the applicability of the study results to other locations may be affected by lifestyle and psychosocial factors influenced by regional, country and/or cultural differences. The other limitation of this study is the possibility that patients will confuse some of the questions, because various kinds of scales are used in each survey to evaluate lifestyle and psychosocial factors. The YOURS study can potentially be expanded in subsequent surveys within the study because patients and HCPs can ask research questions not otherwise included in the survey.

In conclusion, the YOURS study provides an important opportunity to clarify how challenges such as lifestyle, psychosocial factors, practice patterns and gaps between patients' needs and HCPs' practice affect clinical outcomes in patients with UC in Japan. We anticipate that results from the YOURS study will demonstrate optimal UC management strategies to improve relevant outcomes.
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